KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

This study is testing KSD-101, a cell-based therapy (using specially trained immune cells called T-cells) to treat nasopharyngeal carcinoma (a cancer of the back of the nose/throat) that is associated with a virus called Epstein-Barr virus (EBV). It is aimed at patients whose cancer has come back or spread and has no other effective treatments available. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with EBV-associated nasopharyngeal carcinoma confirmed by biopsy - Your cancer has come back locally, spread to other parts of the body, or is a primary case that cannot be treated with standard therapy - You have at least one measurable tumor - You are in reasonably good health (ECOG score 0–1) - Your blood counts, liver, kidney, heart, and clotting functions are within acceptable range **You may NOT be eligible if...** - You have other serious or life-threatening infections - Your heart function is significantly impaired - You have had prior EBV-specific T-cell therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.